Cardiol Therapeutics (CRDL) Receivables - Other (2020 - 2026)

Cardiol Therapeutics' Receivables - Other history runs 7 years deep, the most recent figure standing at $196615.7 for Q1 2026.

• Quarterly Receivables - Other rose 4.21% year-over-year to $196615.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $196615.7 (up 4.21% YoY) and the FY2025 annual result came in at $122240.3, down 34.64% from the prior year.
• Receivables - Other was $196615.7 for Q1 2026 at Cardiol Therapeutics, up from $122240.3 in the prior quarter.
• Across five years, Receivables - Other topped out at $314084.1 in Q1 2022 and bottomed at $100724.7 in Q4 2023.
• A 5-year average of $164793.2 and a median of $155585.5 in 2023 frame the typical range for Receivables - Other.
• Peak annual rise in Receivables - Other reached 791.01% in 2022, while the deepest fall reached 52.99% in 2022.
• Cardiol Therapeutics' Receivables - Other stood at $199111.7 in 2022, then tumbled by 49.41% to $100724.7 in 2023, then soared by 85.67% to $187019.2 in 2024, then plunged by 34.64% to $122240.3 in 2025, then soared by 60.84% to $196615.7 in 2026.
• Business Quant data shows CRDL's Receivables - Other at $196615.7 in Q1 2026, $122240.3 in Q4 2025, and $115088.8 in Q3 2025.